Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

Here, we discuss a handful of the new treatment options in development

By: SHANE R. KANNARR, OD, Christoper J. Jacquinot, OD, Ryan A. Cedeno, OD

Optometric Management July 16, 2025 Vol 60(6), Issue July/August 2025 Page(s): 12

Objective:

To discuss new treatment options in development for dry eye disease (DED).

Key Findings:

Reproxalap may reduce inflammation in DED and allergy patients.
AZR-MD-001 could enhance meibum quality in meibomian gland dysfunction.
OCS-02 targets ocular inflammation related to DED.
Softacort may alleviate symptoms when used with proper lid care.

Interpretation:

These emerging therapies represent a tailored approach to treating the underlying causes of dry eye disease.

Limitations:

Conclusion:

The development of these pharmaceuticals indicates progress in addressing the diverse mechanisms of dry eye disease.

Shane R. Kannarr

Specialties: Optometry

Bio: Shane R. Kannarr, OD, is an optometrist whose clinical writing includes work on multifocal contact lens fitting and comfort. He coauthored a Contact Lens Spectrum peer-reviewed study evaluating delefilcon A daily disposable multifocal contact lenses in symptomatic presbyopic patients, with attention to comfort, dryness, vision, and fitting success.

Contributions:

https://clspectrum.com/issues/2020/november/peer-reviewed-multifocal-lens-fit-and-comfort/

Christoper J. Jacquinot, OD

Specialties: Optometry

Bio: Christoper J. Jacquinot, OD, is an optometrist who has written for Optometric Management on emerging pharmaceutical treatments in the dry eye disease pipeline.

Ryan A. Cedeno

Specialties: Optometry

Bio: Ryan A. Cedeno, OD, is an optometrist whose published work in Optometric Management addresses emerging pharmaceutical treatments for dry eye disease. His writing has covered therapies in development for dry eye disease, including treatments targeting ocular inflammation, meibomian gland dysfunction, and related inflammatory pathways.

PentaVision

Optometric Management

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Recommendations